Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...
Product Name : Totect
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2023
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Iovance Biotherapeutics
Deal Size : $206.3 million
Deal Type : Divestment
Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 million
Details : Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).
Product Name : Proleukin
Product Type : Protein
Upfront Cash : $206.3 million
January 23, 2023
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Iovance Biotherapeutics
Deal Size : $206.3 million
Deal Type : Divestment
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aldesleukin,Riluzole
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.
Product Name : Proleukin
Product Type : Protein
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Aldesleukin,Riluzole
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.
Product Name : Totect
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNG001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaboration will be working to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world.
Product Name : SNG001
Product Type : Protein
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : SNG001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Aldesleukin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinigen's ALS Therapy Bags US Orphan Status
Details : According to the firm, the ODD recognises the potential therapeutic role of aldesleukin in treating disease, and could provide a number of benefits for Clinigen should it obtain a marketing approval for this indication.
Product Name : Proleukin
Product Type : Protein
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Aldesleukin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies
Details : Study aimed at evaluating the safety and efficacy of TIL therapy in metastatic NSCLC (mNSCLC) after evidence of progression on nivolumab.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Iovance Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period, ensuring that Iovance has uninterrupted access to Proleukin to continue ongoing clinical trials.
Product Name : Proleukin
Product Type : Protein
Upfront Cash : Undisclosed
January 14, 2020
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Iovance Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
